The effects of GSK-3β blockade on ketamine self-administration and relapse to drug-seeking behavior in rats

Drug and Alcohol Dependence

Volumn 147, Issue , 2015, Pages 257-265

  Huang, Xianni ^a   Huang, Kunyu ^a   Zheng, Wenhui ^a   Beveridge, Thomas J R ^c,d   Yang, Shujun ^a   Li, Xingxing ^a   Li, Pengping ^a   Zhou, Wenhua ^a,b   Liu, Yu ^a  

^a NINGBO UNIVERSITY   (China)

^b Ningbo Addiction Research and Treatment Center   (China)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d Ferring Pharmaceuticals Inc USA   (United States)

Author keywords

GSK 3 ; Ketamine; Motivation; Relapse; Self administration

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; DIMETHYL SULFOXIDE; GLYCOGEN SYNTHASE KINASE 3BETA; KETAMINE; LITHIUM CHLORIDE; SODIUM CHLORIDE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE;

ABSTINENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PUTAMEN; RAT; RELAPSE; TREATMENT DURATION; VENTRAL TEGMENTUM; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NEOSTRIATUM; PHOSPHORYLATION; RECURRENT DISEASE; REINFORCEMENT;

ANIMALIA; RATTUS;

ANIMALS; DRUG-SEEKING BEHAVIOR; GLYCOGEN SYNTHASE KINASE 3; INDOLES; KETAMINE; LITHIUM CHLORIDE; MALE; MALEIMIDES; NEOSTRIATUM; NUCLEUS ACCUMBENS; PHOSPHORYLATION; RATS; RECURRENCE; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; VENTRAL TEGMENTAL AREA;

EID: 84920943070     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.10.028     Document Type: Article

References (73)

1. Beaulieu J.M. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. JPN 2012, 37:7-16.
2. Benedetti F., Bollettini I., Barberi I., Radaelli D., Poletti S., Locatelli C., Pirovano A., Lorenzi C., Falini A., Colombo C., Smeraldi E. Lithium and GSK3-beta promoter gene variants influence white matter microstructure in bipolar disorder. Neuropsychopharmacology 2013, 38:313-327.
3. Bergman J., Paronis C.A. Measuring the reinforcing strength of abused drugs. Mol. Intervent. 2006, 6:273-283.
4. Bossert J.M., Marchant N.J., Calu D.J., Shaham Y. The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology 2013, 229:453-476.
5. Bouton M.E. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol. Psychiatry 2002, 52:976-986.
6. Cami J., Farre M. Drug addiction. N. Engl. J. Med. 2003, 349:975-986.
7. Chan M.H., Chiu P.H., Lin C.Y., Chen H.H. Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine. Schizophr. Res. 2012, 136:96-103.
8. Chen P.C., Lao C.L., Chen J.C. Dual alteration of limbic dopamine D1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D3 receptor mutants during the development of methamphetamine sensitization. J. Neurochem. 2007, 100:225-241.
9. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee Cox L., Mills D., Brown M.J., et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7:793-803.
10. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001, 2:769-776.
11. Cohen P., Nimmo H.G., Proud C.G. How does insulin stimulate glycogen synthesis?. Biochem. Soc. Symp. 1978, 43:69-95.
12. Collingridge G.L., Isaac J.T., Wang Y.T. Receptor trafficking and synaptic plasticity. Nat. Rev. Neurosci. 2004, 5:952-962.
13. Copeland J., Dillon P. The health and psycho-social consequences of ketamine use. Int. J. Drug Policy 2005, 16:122-131.
14. Dackis C.A., O'Brien C.P. Cocaine dependence: a disease of the brain's reward centers. J. Subst. Abuse Treat. 2001, 21:111-117.
15. DaRocha-Souto B., Coma M., Perez-Nievas B.G., Scotton T.C., Siao M., Sanchez-Ferrer P., Hashimoto T., Fan Z., Hudry E., Barroeta I., Sereno L., Rodriguez M., Sanchez M.B., Human B.T., Gomez-Isla T. Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol. Dis. 2012, 45:425-437.
16. Diniz B.S., Talib L.L., Joaquim H.P., de Paula V.R., Gattaz W.F., Forlenza O.V. Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment?. World J. Biol. Psychiatry 2011, 12:216-222.
17. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
18. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 1980, 107:519-527.
19. Everitt B.J., Robbins T.W. From the ventral to the dorsal striatum: devolving views of their roles in drug addiction. Neurosci. Biobehav. Rev. 2013, 37:1946-1954.
20. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 2001, 359:1-16.
21. Frame S., Cohen P., Biondi R.M. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 2001, 7:1321-1327.
22. Freyberg Z., Ferrando S.J., Javitch J.A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am. J. Psychiatry 2010, 167:388-396.
23. Ghitza U.E., Zhai H., Wu P., Airavaara M., Shaham Y., Lu L. Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci. Biobehav. Rev. 2010, 35:157-171.
24. Hong J.G., Kim D.H., Lee C.H., et al. GSK-3beta activity in the hippocampus is required for memory retrieval. Neurobiol. Learn. Mem. 2012, 98:122-129.
25. Hyman S.E., Malenka R.C., Nestler E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Ann. Rev. Neurosci. 2006, 29:565-598.
26. Kalivas P.W., Lalumiere R.T., Knackstedt L., Shen H. Glutamate transmission in addiction. Neuropharmacology 2009, 56(Suppl. 1):169-173.
27. Kapur S., Seeman P. Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor. Biol. Psychiatry 2001, 49:954-957.
28. Kozlovsky N., Belmaker R.H., Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry 2000, 157:831-833.
29. Lecca D., Cacciapaglia F., Valentini V., Acquas E., Di Chiara G. Differential neurochemical and behavioral adaptation to cocaine after response contingent and noncontingent exposure in the rat. Psychopharmacology (Berl.) 2007, 191:653-667.
30. Leroy K., Brion J.P. Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J. Chem. Neuroanat. 1999, 16:279-293.
31. Li S.X., Wei Y.M., Shi H.S., Luo Y.X., Ding Z.B., Xue Y.X., Lu L., Yu C.X. Glycogen synthase kinase-3beta in the ventral tegmental area mediates diurnal variations in cocaine-induced conditioned place preference in rats. Addict. Biol. 2013, (Epub ahead of print).
32. Li X., Jope R.S. Is glycogen synthase kinase-3 a central modulator in mood regulation?. Neuropsychopharmacology 2010, 35:2143-2154.
33. Li Y.C., Gao W.J. GSK-3beta activity and hyperdopamine-dependent behaviors. Neurosci. Biobehav. Rev. 2011, 35:645-654.
34. Liu J., Moghaddam B. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J. Pharmacol. Exp. Ther. 1995, 274:1209-1215.
35. Liu J.R., Baek C., Han X.H., Shoureshi P., Soriano S.G. Role of glycogen synthase kinase-3beta in ketamine-induced developmental neuroapoptosis in rats. Br. J. Anaesth. 2013, 110(Suppl. 1):i3-i9.
36. Ly P.T., Wu Y., Zou H., Wang R., Zhou W., Kinoshita A., Zhang M., Yang Y., Cai F., Woodgett J., Song W. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 2013, 123:224-235.
37. Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20:127-150.
38. Malenka R.C., Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44:5-21.
39. Martinez A., Castro A., Dorronsoro I., et al. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 2002, 22:373-384.
40. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33:2080-2092.
41. Miller J.S., Tallarida R.J., Unterwald E.M. Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology 2009, 56:1116-1123.
42. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Neuroscience 1997, 17:2921-2927.
43. Morgan C.J., Muetzelfeldt L., Curran H.V. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010, 105:121-133.
44. Muller C.P., Homberg J.R. The role of serotonin in drug use and addiction. Behav. Brain Res. 2014, (Epub ahead of print).
45. Nishiguchi N., Breen G., Russ C., Clair D., Collier D. Association analysis of the glycogen synthase kinase-3beta gene in bipolar disorder. Neurosci. Lett. 2006, 394:243-245.
46. Panlilio L.V., Katz J.L., Pickens R.W., et al. Variability of drug self-administration in rats. Psychopharmacology 2003, 167:9-19.
47. Parker P.J., Caudwell F.B., Cohen P. Glycogen synthase from rabbit skeletal muscle: effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. Eur. J. Biochem. 1983, 130:227-234.
48. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 1999, 58:1010-1019.
49. Peineau S., Nicolas C.S., Bortolotto Z.A., Bhat R.V., Ryves W.J., Harwood A.J., Dournaud P., Fitzjohn S.M., Collingridge G.L. A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases. Mol. Brain 2009, 2:22.
50. Peineau S., Taghibiglou C., Bradley C., Wong T.P., Liu L., Lu J., Lo E., Wu D., Saule E., Bouschet T., Matthews P., Isaac J.T., et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007, 53:703-717.
51. Perrine S.A., Miller J.S., Unterwald E.M. Cocaine regulates protein kinase B and glycogen synthase kinase-3 activity in selective regions of rat brain. J. Neurochem. 2008, 107:570-577.
52. Plyte S.E., Hughes K., Nikolakaki E., Pulverer B.J., Woodgett J.R. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim. Biophys. Acta 1992, 1114:147-162.
53. Porrino L.J. Functional consequences of acute cocaine treatment depend on route of administration. Psychopharmacology (Berl.) 1993, 112:343-351.
54. Richardson N.R., Roberts D.C. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J. Neurosci. Methods 1996, 66:1-11.
55. Roberts D.C., Morgan D., Liu Y. How to make a rat addicted to cocaine. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2007, 31:1614-1624.
56. Rylatt D.B., Aitken A., Bilham T., Condon G.D., Embi N., Cohen P. Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. Eur. J. Biochem. 1980, 107:529-537.
57. Saus E., Soria V., Escaramis G., Crespo J.M., Valero J., Gutierrez-Zotes A., Martorell L., Vilella E., Menchon J.M., Estivill X., Gratacos M., Urretavizcaya M. A haplotype of glycogen synthase kinase 3beta is associated with early onset of unipolar major depression. Genes Brain Behav. 2010, 9:799-807.
58. Shang Y., Wu Y., Yao S., Wang X., Feng D., Yang W. Protective effect of erythropoietin against ketamine-induced apoptosis in cultured rat cortical neurons: involvement of PI3K/Akt and GSK-3 beta pathway. Apoptosis 2007, 12:2187-2195.
59. Sillivan S.E., Black Y.D., Naydenov A.V., Vassoler F.R., Hanlin R.P., Konradi C. Binge cocaine administration in adolescent rats affects amygdalar gene expression patterns and alters anxiety-related behavior in adulthood. Biol. Psychiatry 2011, 70:583-592.
60. Spealman R.D., Goldberg S.R. Drug self-administration by laboratory animals: control by schedules of reinforcement. Ann. Rev. Pharmacol. Toxicol. 1978, 18:313-339.
61. Sun W.L., Coleman N.T., Zelek-Molik A., Barry S.M., Whitfield T.W., McGinty J.F. Relapse to cocaine-seeking after abstinence is regulated by cAMP-dependent protein kinase A in the prefrontal cortex. Addict. Biol. 2014, 19:77-86.
62. Takadera T., Ishida A., Ohyashiki T. Ketamine-induced apoptosis in cultured rat cortical neurons. Toxicol. Appl. Pharmacol. 2006, 210:100-107.
63. Thomas M.J., Kalivas P.W., Shaham Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br. J. Pharmacol. 2008, 154:327-342.
64. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 2000, 57:1139-1147.
65. UNODC Patterns and Trends of Amphetamine-Type Stimulants and Other Drugs: Challenges for Asia and the Pacific 2013, United National Publications, New York, NY.
66. Willi R., Harmeier A., Giovanoli S., Meyer U. Altered GSK3beta signaling in an infection-based mouse model of developmental neuropsychiatric disease. Neuropharmacology 2013, 73C:56-65.
67. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9:2431-2438.
68. Wu P., Xue Y.X., Ding Z.B., Xue L.F., Xu C.M., Lu L. Glycogen synthase kinase 3beta in the basolateral amygdala is critical for the reconsolidation of cocaine reward memory. J. Neurochem. 2011, 118:113-125.
69. Xu C.M., Wang J., Wu P., Xue Y.X., Zhu W.L., Li Q.Q., Zhai H.F., Shi J., Lu L. Glycogen synthase kinase 3beta in the nucleus accumbens core is critical for methamphetamine-induced behavioral sensitization. J. Neurochem. 2011, 118:126-139.
70. Xu C.M., Wang J., Wu P., Zhu W.L., Li Q.Q., Xue Y.X., Zhai H.F., Shi J., Lu L. Glycogen synthase kinase 3beta in the nucleus accumbens core mediates cocaine-induced behavioral sensitization. J. Neurochem. 2009, 111:1357-1368.
71. Yang C., Zhou Z.Q., Gao Z.Q., Shi J.Y., Yang J.J. Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3beta, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients. Biol. Psychiatry 2013, 73:e35-e36.
72. Yao H.B., Shaw P.C., Wong C.C., Wan D.C. Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J. Chem. Neuroanat. 2002, 23:291-297.
73. Zhu T.M., Jin R.J., Zhong X.M., et al. Effects of electroacupuncture combined with psychologic interference on anxiety state and serum NE content in the patient of internet addiction disorder. Zhongguo Zhen Jiu 2008, 28:561-564. (Chinese acupuncture & moxibustion).